Ascendis Pharma A (ASND) Restructuring Costs (2021 - 2025)

Ascendis Pharma A (ASND) reported Restructuring Costs of -$18.3 million for Q1 2025, down 896671.82% sequentially from -$2040.5 in Q4 2022.

Ascendis Pharma A (ASND) Restructuring Costs (2021 - 2025) Analysis & Trends

Ascendis Pharma A (ASND) has 3 years of Restructuring Costs data on file, last reported at -$18.3 million in Q1 2025.

For the quarter ending Q1 2025, Restructuring Costs changed N/A year-over-year to -$18.3 million; the trailing twelve-month figure through Sep 2025 stood at -$18.3 million (down 896671.82% YoY), and the FY2022 full-year result was -$111.0 million, down 349.06% from the prior year.
Restructuring Costs declined to -$18.3 million in Q1 2025, from -$2040.5 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $1008.3 in Q3 2022 to a low of -$118.0 million in Q1 2022.
A 3-year average of -$26.9 million and a median of -$9.2 million in 2025 frame the typical range for Restructuring Costs.
Peak annual rise in Restructuring Costs reached 99.99% in 2022, while the deepest fall reached 99.99% in 2022.
Tracing ASND's Restructuring Costs over 3 years: stood at -$24.7 million in 2021, then jumped by 99.99% to -$2040.5 in 2022, then tumbled by 896671.82% to -$18.3 million in 2025.
Business Quant data shows ASND's Restructuring Costs at -$18.3 million in Q1 2025, -$2040.5 in Q4 2022, and $1008.3 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ascendis Pharma A	15.31 Bn	14.64 Bn	268.20 Mn

Download Data